兴齐眼药：伏立康唑滴眼液完成II期临床试验首例受试者入组

Core Viewpoint - The company, Xingqi Eye Pharmaceutical, has announced the completion of the first subject enrollment in the Phase II clinical trial for its drug, Voriconazole Eye Drops, aimed at treating fungal keratitis [1] Group 1: Clinical Trial Details - Voriconazole Eye Drops are classified as a chemical drug of category 2.2, specifically targeting fungal keratitis [1] - The Phase II clinical trial is a randomized, positive-controlled, multi-center exploratory study designed to preliminarily assess the efficacy and safety of Voriconazole Eye Drops in subjects with fungal keratitis [1] - The trial aims to explore safe and effective drug concentrations for the subsequent Phase III clinical trial [1] Group 2: Market Context - Currently, there are no approved Voriconazole Eye Drops available in the market [1]